The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

More information: Thomas A. Hope et al, SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET, Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.124.269002 ...

A new PET/CT imaging technique that visualizes activated fibroblasts in the heart muscle enables early detection of multiple ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review" report has been added to ResearchAndMarkets.com's offering.

The procedure standard/practice guideline outlines several oncologic indications for FAP PET imaging, including gastro-intestinal adenocarcinoma, pancreatic ductal adenocarcinoma, esophageal, head ...